KCM
TGTX icon

Kennedy Capital Management’s TG Therapeutics TGTX Stock Holding History

Kennedy Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-585,439
Closed -$4.8M – 762
2017
Q4 		$4.8M Buy
585,439
+164,210
+39% +$1.43M 0.09% 440
2017
Q3 		$4.99M Sell
421,229
-143,949
-25% -$1.64M 0.09% 418
2017
Q2 		$5.68M Buy
565,178
+340,545
+152% +$3.81M 0.11% 349
2017
Q1 		$2.62M Buy
+224,633
New +$1.61M 0.05% 555

Other funds holding TGTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Kennedy Capital Management's TGTX Position: Q1 2018 in Review

Kennedy Capital Management sold out of TG Therapeutics (TGTX) in Q1 2018, closing a stake of 585,439 shares — an estimated $4.8M sold.

Kennedy Capital Management first reported a position in TGTX in Q1 2017 and held it in 4 quarters. The position peaked at $5.68M in Q2 2017. 125 funds tracked by Wall St. Rank hold TGTX as of Q1 2018.

  • Kennedy Capital Management reported no remaining TG Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Kennedy Capital Management sold 585,439 TG Therapeutics shares in Q1 2018, an estimated $4.8M.
  • Kennedy Capital Management first reported a position in TG Therapeutics in Q1 2017 and held it in 4 quarters.
  • Kennedy Capital Management's TG Therapeutics position peaked at $5.68M in Q2 2017.
  • 125 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2018.

Based on Kennedy Capital Management's 13F filing for Q1 2018, filed 14 May 2018.